Executive Summary

Chapter 1. Background: Trends in Cancer Diagnostics
1.1. Summary of Key Trends
1.2. Statistics Showing Impact of the Disease and the Need for Early Diagnosis
1.3. Prospects for Cancer Theranostics

Chapter 2. Developments in Cancer Imaging
2.1. Introduction
2.2. Virtual Colonoscopy (Application of Computed Tomography in Colon Cancer Screening)
Description and Status
Potential Impact
Competition
Outlook
2.3. Advances in Breast Cancer Imaging
Description and Status
Potential Impact
Competition
Outlook
2.4. Emerging Role of Positron Emission Tomography in Cancer Diagnostics
Description and Status
Potential Impact
Competition
Outlook
2.5. In Vivo Diagnostic Monoclonal Antibodies for Imaging Cancers
Description and Status
Potential Impact
Competition
Outlook

Chapter 3. Developments In Cancer In Vitro Diagnostics
3.1. Introduction
"Traditional Tumor" Markers
Technologies Used for Cancer In Vitro Diagnostics
Trends in Cancer In Vitro Diagnostics
3.2. Advances in In Vitro Colorectal Cancer Screening
Description and Status
Potential Impact
Competition
Outlook
3.3. Theranostic Applications of Cancer In Vitro Diagnostics: Erbitux and Epidermal Growth Factor Receptor
Description and Status
Potential Impact
Competition
Outlook
3.4. Theranostic Applications of Cancer In Vitro Diagnostics: Applications in Leukemia and Lymphoma Diagnostics
Description and Status
Potential Impact
Competition
Outlook
3.5. Changes in DNA Methylation: Application in Cancer Diagnostics
Description and Status
Potential Impact
Competition
Outlook
3.6. Selected Advances in the Search for Novel Cancer Biomarkers/Tests

Chapter 4. Business Outlook
4.1. Business Trends
Positron Emission Tomography
Breast Imaging: Mammography
In Vivo Diagnostic Monoclonal Antibodies
In Vitro Cancer Diagnostics
4.2. Company Profiles
Abbott Laboratories
Advanced Research Technologies
Applied Imaging
Cardinal Health
Celera Diagnostics
CTI Molecular Imaging
DakoCytomation
Epigenomics
Exact Sciences
GE Healthcare
Neoprobe
OncoMethylome Sciences
Philips Medical Systems
Roche Diagnostics
Siemens

Chapter 5. Expert Interviews
Roger Attick, CEO and President, CeMines, Inc.
David Bupp, President and CEO, Neoprobe
Gary Schweikhardt, President, Epigenomics, Inc.; Head of Diagnostics Strategic Business Unit, Epigenomics AG
L. Blair Shamel, Senior Vice President, Corporate Development, DiagnoCure
Daryl Sonnichsen, Pharm. D., Senior Director, Wyeth Clinical Pharmacology

References

Glossary

Index